We hypothesized that 1) VEGF-A and its main functional receptor, VEGFR-2, are expressed in the fetal intestines; 2) one or both of these proteins are up-regulated in association with advancing ...

Here we introduce a new approach for the screening, selection and sorting of cell-surface–binding peptides from phage libraries. Biopanning and rapid analysis of selective interactive ligands ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Gender differences define how the human brain ages, and telltale biomarkers in the blood may be strongly suggestive of ...

According to Ottimo, jankistomig is a "first-in-class […] bifunctional antibody" directed at PD-1 and VEGFR2, a receptor for VEGF, and is "differentiated from bispecific antibodies" against the ...

Metastatic clear cell renal cell carcinoma (mccRCC), an aggressive type of kidney cancer, has historically presented limited treatment options. Immune checkpoint inhibitors, a form of immunotherapy, ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

PM-8002 is under clinical development by Biotheus and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition ...

Naya Biosciences Inc. has expanded its bifunctional antibody pipeline to include NY-500, a novel PD-1 x VEGF tetravalent bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) and ...

This innovative therapeutic approach is designed to inhibit both PD-1/PD-L1 and VEGF/VEGFR receptor signaling pathways releasing a key immune checkpoint while also inhibiting the production of new ...